<unk>  channel<unk>  (CCBs) consist of three sub-classes namely, dihydropyridines (e.g., nifedipine), phenylalkylamines (e.g., verapamil) and modified benzothiazepines (e.g., diltiazem). The beneficial anti-anginal effects of CCB include: reduction in the afterload consequent to systemic vasodilation as well as epicardial vessel vasodilation, enhancement of the coronary collateral flow with subsequent sub-endocardial perfusion due to the inhibition of<unk>  influx via L-type channels. Long-acting<unk>  channel<unk>  are an effective antianginal agent and are considered to be the first choice in post-MI patients with a contraindication to beta-blocker. Long-acting CCBs are also specifically used to control symptoms in patients with vasospastic angina. However short-acting CCBs, such as nifedipine, are avoided due to an increased risk of myocardial infarction and mortality.
Chronic stable angina treatment calcium channel blockers
Chronic stable angina treatment beta blockers
Chronic stable angina treatment aspirin
Chronic stable angina treatment anti-lipid agents
Chronic stable angina treatment dipyridamole
Chronic stable angina treatment angiotensin converting enzyme inhibitors 
Chronic stable angina treatment potassium channel openers
Chronic stable angina revascularization percutaneous coronary intervention